Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety and PK Study of L608 Inhalation in Healthy Volunteers
NCT05938946Phase 1Completed
- Sponsor
- Pharmosa Biopharm Inc.
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing L608 Inhalation with Placebo (2 arms). Primary endpoints: The incidence of dose limiting toxicity at Day 14, The incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) at Day 21 and 1 more. Started Aug 2023; status: completed.
02
Drugs
L608
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05938946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938946.